SavedAdd your journal

Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2017 / Cilt: 14 - Sayı: 1

Myo-Inositol And Folic Acid Supplementation For The Policystic Ovary Syndrome Patients Undergoing In-Vitro Fertilization Cycles

In Vitro Fertilizasyon Uygulanacak Polikistik Over Sendromlu Hastalar İçin Myo-İnositol Ve Folik Asit Desteği

Bülent BERKER
Mehmet Murat SEVAL
Murat SÖNMEZER
Cem ATABEKOĞLU
Yavuz Emre ŞÜKÜR
Batuhan ÖZMEN
Melahat ATASEVER
Dilek ACAR
Pages
1–4
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aim: We evaluated the effects the administration of “Myo-inositol plus Folic acid” MI-FA supplementation on ovarian reserve markers and in-vitro fertilization IVF cycle in patients with polycystic ovary syndrome PCOS patients.Material and Methods: Totally 58 PCOS women aged

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We evaluated the effects the administration of “Myo-inositol plus Folic acid” MI-FA supplementation on ovarian reserve markers and in-vitro fertilization IVF cycle in patients with polycystic ovary syndrome PCOS patients.Material and Methods: Totally 58 PCOS women aged
📊
Key Findings & Data:Aim: We evaluated the effects the administration of “Myo-inositol plus Folic acid” MI-FA supplementation on ovarian reserve markers and in-vitro fertilization IVF cycle in patients with polycystic ovary syndrome PCOS patients.Material and Methods: Totally 58 PCOS women aged
💡
Conclusion & Impact:Aim: We evaluated the effects the administration of “Myo-inositol plus Folic acid” MI-FA supplementation on ovarian reserve markers and in-vitro fertilization IVF cycle in patients with polycystic ovary syndrome PCOS patients.Material and Methods: Totally 58 PCOS women aged
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İn vitro fertilizasyon · polikistik over sendromu · myo-inositol

Abstract

Aim: We evaluated the effects the administration of “Myo-inositol plus Folic acid” MI-FA supplementation on ovarian reserve markers and in-vitro fertilization IVF cycle in patients with polycystic ovary syndrome PCOS patients.Material and Methods: Totally 58 PCOS women aged

Özet

Amaç: Myo-inositol’un IVF hastalarında serum düzeylerinden bağımsız olarak ovaryan fonksiyon ve oosit kalitesini artırdığı izlenmiştir. Biz de bu PCOS’lu IVF hastalarında myo-inositol’un hormonal ve klinik parametreler üzerine etkisini araştırmayı hedefledik.Gereç ve Yöntemler: Ocak 2013 ve Mayıs 2015 arasında üniversitemiz üreme sağlığına IVF/ICSI için başvurmuş hastalar retrospektif olarak değerlendirildi.Tüm hastalar ikinci IVF siklusundan önce en az 12 hafta myo-inozitol ve folik asid replasmanını 1gr/gün aldı ve çalışma sonucunda klinik gebelik oranları, implantasyon oranı, toplanan oosit sayısı, metafaz 2 oosit sayısı, grade A embriyo sayısı ve siklus iptal oranları değerlendirildi.Bulgular: Çalışma sonucunda MI-FA replasmanı sonrası gebelik oranları artmış olsa da istatiksel olarak anlamlı bulunmamıştır. Benzer şekilde M2 oosit sayısında azalma 14 ve 17 mm’lik folikül sayısı ve transfer edilen embriyo sayısında artış, siklus iptal oranlarında azalma izlense de istatiksel olarak anlamlı bulunmamıştır.Sonuç: Çalışmamızda ele alınan hasta sayısı az olmakla birlikte, bazı parametrelerde tedavi öncesine göre düzelme izlenmiş ancak istatiksel anlamlılık bulunmamıştır.

🔖

Cite This Article

BERKER, B., SEVAL, M. M., SÖNMEZER, M., ATABEKOĞLU, C., ŞÜKÜR, Y. E., ÖZMEN, B., ATASEVER, M., ACAR, D. (2022). Myo-Inositol And Folic Acid Supplementation For The Policystic Ovary Syndrome Patients Undergoing In-Vitro Fertilization Cycles. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 14 - Sayı: 1, 1–4. https://ajindex.com/articles/558747

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteriaand long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.
  2. Rienzi L, Vajta G, Ubaldi F Predictive value of oocytemorphology in hu- man IVF: a systematic review of the literature. Hum Reprod Update 2010; 17:34–45.
  3. Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycysticovary syndrome show both hyperandrogenism and hyperinsulinemia.Gynecol Endocrinol 2007;23:146–52.
  4. Hasegawa I, Murakawa H, Suzuki M, et al. Effect of troglitazone onendoc- rine and ovulatory performance in women with insülin resistance related polycystic ovary syndrome. Fertil Steril 1999;71:323–7.
  5. Mariangela Treglia, Robert Najjar, Arturo Bevilacqua The combined the- rapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial Sandra Colazingari. Arch Gynecol Obstet (2013) 288:1405–1411.
  6. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L Myo-i- nositol may improve oocyte quality in intracytoplasmicsperm injec- tion cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–1754.
  7. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95:2515–2516.
  8. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. Aprospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011;15:452–457 Kane MT: The effects of water-soluble vitamins on the expansion ofrabbit blastocysts in vitro. J Exp Zool 1988, 245:220–223. Berridge MJ: Inositol lipids and cell proliferation. Biochim Biophys Acta 1987, 907:33–45. Downes CP: Twenty-fifth Colworth medal lecture. The cellular functions of myo-inositol. Biochem Soc Trans 1989, 17:259–268. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study P. G. Artini1, O. M. Di Berardino1, F. Papini1, A. D. Genazzani2, G. Simi1, M. Ruggiero1, and V. Cela1 Gynecol Endocrinol, 2013; 29: 375–379.
  9. Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–513.
  10. Gerli S, Mignosa M, Di Renz